IQ-AI Limited MD ANDERSON ADOPTS IB CLINIC (0487R)
02 November 2021 - 7:19PM
UK Regulatory
TIDMIQAI
RNS Number : 0487R
IQ-AI Limited
02 November 2021
FOR IMMEDIATE RELEASE
MD ANDERSON ADOPTS IB CLINIC FOR BRAIN TUMOR ANALYSIS
Installation Includes IB Neuro(TM) and IB DCE(TM) Software
Purchase also Includes IB Clinic - Mac Edition
Milwaukee - 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB:
IQAIF) , a developer and manufacturer of medical image processing
platforms that have led to effective therapeutic strategies for
brain tumor and other patients, today announced the University of
Texas MD Anderson Cancer Center (Houston, TX) is the latest brain
cancer center to purchase an annual subscription of IB Clinic
software. IB Clinic is an automated processing application that
generates quantitative magnetic resonance (MR) perfusion images and
other maps useful in assessing brain tumors and monitoring
treatment.
The installation includes IB Neuro(TM) and IB DCE(TM) software
that networks within the MD Anderson IT infrastructure and outputs
quantitative maps directly to their resident PACS (picture and
communication system) for viewing and diagnostic interpretation.
The purchase also includes IB Clinic - Mac edition, which comprises
all IB modules as plugins to the OsiriX DICOM (digital information
and communications in medicine) environment. Specifically, IB
Clinic - Mac Edition allows for user input while running IB Rad
Tech: IB Rad Tech is a workflow processor that allows customized
workflows for the generation of IB's advanced maps and statistical
reports.
Ranked as the #1 cancer center in the USA by U.S. News &
World Report , MD Anderson Cancer Center is renowned for excellence
in brain cancer care. Its specialized and multidisciplinary teams
use cutting edge technologies to offer patients personalized care
in attempt to improve outcomes.
"We are very pleased that MD Anderson has adopted IB Clinic,"
said Trevor Brown, CEO of IQ-AI Limited. "The automated processing
is ideal for high-volume centers such as this, and the quantitative
capability allows direct comparison of longitudinal scans, no
matter where or when the patient is scanned."
Earlier this year, IQ-AI announced the marked increase in IB
Clinic installations and attributes this to the automated
generation of its exclusive quantitative output. The company
recently published a letter to shareholders to announce its most
successful year on record.
About Imaging Biometrics, LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON: IQAI)
(OTCQB: IQAIF), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat
disease with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent and automated software
plug-ins which can extend the base functionality of workstations,
imaging systems, PACS, or medical viewers. By design, IB's advanced
visualisation software seamlessly integrates into routine
workflows. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com .
Safe Harbor Statement
This press release includes statements that may constitute
forward-looking statements made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates," or the negative of these words
and/or similar statements. Statements that are not historical
facts, including statements about the Company's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. For example, statements about future revenues and the
Company's ability to fund its operations and contractual
obligations are forward looking and subject to risks. Several
important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Potential
risks and uncertainties include, but are not limited to, the
inability to raise capital to support the Company through its
growth stage, the Company's inability to generate projected sales
and trade relations between the United States and China. The
Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
Investor Relations Contact:
Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: 212-564-4700
mike@plrinvest.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDKBBDFBDKODK
(END) Dow Jones Newswires
November 02, 2021 04:19 ET (08:19 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2023 to Apr 2024